May 2005
Volume 46, Issue 13
ARVO Annual Meeting Abstract  |   May 2005
VEGF164 Governs Leukocyte Dynamics and Pathological Neovascularization
Author Affiliations & Notes
  • K. Nishijima
    Eyetech Research Center, Lexington, MA
  • N. Jo
    Eyetech Research Center, Lexington, MA
  • Y.–S. Ng
    Eyetech Research Center, Lexington, MA
  • G.S. Robinson
    Eyetech Research Center, Lexington, MA
  • P.A. D'amore
    Ophthal & Pathology, Schepens Eye Research Inst, Boston, MA
  • D.T. Shima
    Eyetech Research Center, Lexington, MA
  • A.P. Adamis
    Eyetech Research Center, Lexington, MA
  • Footnotes
    Commercial Relationships  K. Nishijima, Eyetech Pharmaceuticals E; N. Jo, Eyetech Pharmaceuticals E; Y. Ng, Eyetech Pharmaceuticals E; G.S. Robinson, Eyetech Pharmaceuticals E; P.A. D'amore, None; D.T. Shima, Eyetech Pharmaceuticals E; A.P. Adamis, Eyetech Pharmaceuticals E.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 1372. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      K. Nishijima, N. Jo, Y.–S. Ng, G.S. Robinson, P.A. D'amore, D.T. Shima, A.P. Adamis; VEGF164 Governs Leukocyte Dynamics and Pathological Neovascularization . Invest. Ophthalmol. Vis. Sci. 2005;46(13):1372.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: Both physiological vascular development and pathological angiogenesis in the retina have been shown to be controlled by vascular endothelial growth factor (VEGF). Previous studies have demonstrated that ischemia–induced retinal neovascularization is caused in part by local inflammatory responses. This study aims to characterize the roles of the different VEGF isoforms in inflammation and pathological neovascularization by examining the pro–inflammatory and angiogenic nature of the VEGF164 isoform through the use of VEGF164–deficient (VEGF120/188) mice. Methods: Retinopathy of prematurity (ROP) and laser induced–choroidal neovascularization (CNV) models were used to investigate the role of VEGF164 isoform in pathological neovascularization. In addition, to characterize the role of VEGF164 in inflammation outside the eye, we evaluated delayed–type hypersensitivity (DTH) reactions induced by oxazolone in the ear skin of wild–type and VEGF120/188 mice. Results: VEGF120/188 mice exhibited normal development of the retinal vasculature, as compared with age–matched wild–type mice, suggesting that the VEGF164 isoform is not required for normal vascular development in the retina. However, pathological neovascularization was suppressed by over 90% in the VEGF120/188 mice when compared with wild–type littermates in the ROP model. Furthermore, leukostasis and up–regulation of intracellular adhesion molecule–1 (ICAM–1) by the vessels were significantly reduced in the retinas of VEGF164–deficient mice with ROP, when compared to wild–type littermates. In the CNV model, choroidal neovascularization in the VEGF120/188 mice was reduced by 44%, as compared with that of wild–type mice. In the DTH model, the lack of the VEGF164 isoform resulted in a significant decrease in the inflammatory response which included leukocyte accumulation and tissue edema in ear skin, providing evidence that the pro–inflammatory nature of VEGF164 isoform is not unique to ocular tissues. Conclusions: Our data demonstrate that the combination of the VEGF120 and VEGF188 isoforms are sufficient to drive normal physiological retinal vessel growth, and VEGF164 is a pathological VEGF isoform that promotes pathological neovasculariztion as well as inflammation both in the eye and in the skin.

Keywords: neovascularization • inflammation • choroid: neovascularization 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.